1. Market Research
  2. > Pharmaceutical Market Trends
  3. > aRigen Pharmaceuticals, Inc. - Product Pipeline Review - 2013

aRigen Pharmaceuticals, Inc. - Product Pipeline Review - 2013

  • August 2013
  • -
  • Global Markets Direct
  • -
  • 37 pages

aRigen Pharmaceuticals, Inc. - Product Pipeline Review - 2013

Summary

Global Market Direct’s pharmaceuticals report, “aRigen Pharmaceuticals, Inc. - Product Pipeline Review - 2013” provides data on the aRigen Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, aRigen Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from aRigen Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- aRigen Pharmaceuticals, Inc. - Brief aRigen Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of aRigen Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of aRigen Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the aRigen Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate aRigen Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of aRigen Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the aRigen Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with aRigen Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of aRigen Pharmaceuticals, Inc. and identify potential opportunities in those areas.

Table Of Contents

aRigen Pharmaceuticals, Inc. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
aRigen Pharmaceuticals, Inc. Snapshot 5
aRigen Pharmaceuticals, Inc. Overview 5
Key Information 5
Key Facts 5
aRigen Pharmaceuticals, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
aRigen Pharmaceuticals, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
aRigen Pharmaceuticals, Inc. - Pipeline Products Glance 11
aRigen Pharmaceuticals, Inc. - Late Stage Pipeline 11
Phase III Products/Combination Treatment Modalities 11
aRigen Pharmaceuticals, Inc. Clinical Stage Pipeline Products 12
Phase I Products/Combination Treatment Modalities 12
aRigen Pharmaceuticals, Inc. - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Discovery Products/Combination Treatment Modalities 14
aRigen Pharmaceuticals, Inc. - Drug Profiles 15
ARA-01 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
ARA-02 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
ARA-03 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
ARA-04 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
ARB-MGR06 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
ARH-1029 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
ARMAK-105 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
gemifloxacin mesylate 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
lotilibcin 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
nelfinavir mesylate 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
sorivudine 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
tobramycin liposomal 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
aRigen Pharmaceuticals, Inc. - Pipeline Analysis 27
aRigen Pharmaceuticals, Inc. - Pipeline Products by Therapeutic Class 27
aRigen Pharmaceuticals, Inc. - Pipeline Products By Target 29
aRigen Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 30
aRigen Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action 31
aRigen Pharmaceuticals, Inc. - Recent Pipeline Updates 33
aRigen Pharmaceuticals, Inc. - Dormant Projects 34
aRigen Pharmaceuticals, Inc. - Locations And Subsidiaries 35
Head Office 35
Appendix 36
Methodology 36
Coverage 36
Secondary Research 36
Primary Research 36
Expert Panel Validation 36
Contact Us 37
Disclaimer 37



List of Tables

aRigen Pharmaceuticals, Inc., Key Information 5
aRigen Pharmaceuticals, Inc., Key Facts 5
aRigen Pharmaceuticals, Inc. - Pipeline by Indication, 2013 8
aRigen Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2013 9
aRigen Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2013 10
aRigen Pharmaceuticals, Inc. - Phase III, 2013 11
aRigen Pharmaceuticals, Inc. - Phase I, 2013 12
aRigen Pharmaceuticals, Inc. - Preclinical, 2013 13
aRigen Pharmaceuticals, Inc. - Discovery, 2013 14
aRigen Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, 2013 28
aRigen Pharmaceuticals, Inc. - Pipeline By Target, 2013 29
aRigen Pharmaceuticals, Inc. - Pipeline By Route of Administration, 2013 30
aRigen Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action, 2013 32
aRigen Pharmaceuticals, Inc. - Recent Pipeline Updates, 2013 33
aRigen Pharmaceuticals, Inc. - Dormant Developmental Projects,2013 34



List of Figures

aRigen Pharmaceuticals, Inc. - Pipeline by Indication, 2013 7
aRigen Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2013 9
aRigen Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2013 10
aRigen Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, 2013 27
aRigen Pharmaceuticals, Inc. - Pipeline By Route of Administration, 2013 30
aRigen Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action, 2013 31



Companies Mentioned

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.